MEREO BIOPHARMA GROUP PLC Investment Income, Interest
MEREO BIOPHARMA GROUP PLC (MREO) reported Investment Income, Interest of $278.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-11
- MEREO BIOPHARMA GROUP PLC investment income, interest for the quarter ending 2026-06-30 was $278.00K, a 52.80% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC investment income, interest for the quarter ending 2026-03-31 was $327.00K, a 50.38% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC investment income, interest for the quarter ending 2025-12-31 was $421.00K, a 52.21% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC investment income, interest for the quarter ending 2025-09-30 was $504.00K, a 48.73% decline year-over-year.
- MEREO BIOPHARMA GROUP PLC investment income, interest for fiscal 2025 was $2.17M, a 28.54% decline from fiscal 2024.
- MEREO BIOPHARMA GROUP PLC investment income, interest for fiscal 2024 was $3.04M, a 42.70% increase from fiscal 2023.
- MEREO BIOPHARMA GROUP PLC investment income, interest for fiscal 2023 was $2.13M, a 153.69% increase from fiscal 2022.
- MEREO BIOPHARMA GROUP PLC investment income, interest for fiscal 2022 was $840.00K.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $278.00K 10-Q · filed 2026-08-11 | $605.00K 10-Q · filed 2026-08-11 | $1.03M derived: sum of 3 quarters · filed 2026-08-11 | $1.53M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $327.00K 10-Q · filed 2026-05-12 | $748.00K derived: sum of 2 quarters · filed 2026-05-12 | $1.25M derived: sum of 3 quarters · filed 2026-05-12 | $1.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $925.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.51M derived: sum of 3 quarters · filed 2026-08-11 | $2.17M 10-K · filed 2026-03-19 |
| 2025-09-30 | $504.00K 10-Q · filed 2025-11-10 | $1.09M derived: sum of 2 quarters · filed 2026-08-11 | $1.75M 10-Q · filed 2025-11-10 | $2.63M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $589.00K 10-Q · filed 2026-08-11 | $1.25M 10-Q · filed 2026-08-11 | $2.13M derived: sum of 3 quarters · filed 2026-08-11 | $3.11M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $659.00K 10-Q · filed 2026-05-12 | $1.54M derived: sum of 2 quarters · filed 2026-05-12 | $2.52M derived: sum of 3 quarters · filed 2026-05-12 | $3.08M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $881.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $1.86M derived: sum of 2 quarters · filed 2026-03-19 | $2.42M derived: sum of 3 quarters · filed 2026-03-19 | $3.04M 10-K · filed 2026-03-19 |
| 2024-09-30 | $983.00K 10-Q · filed 2025-11-10 | $1.54M derived: sum of 2 quarters · filed 2025-11-10 | $2.16M 10-Q · filed 2025-11-10 | $2.92M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $559.00K 10-Q · filed 2025-08-12 | $1.18M 10-Q · filed 2025-08-12 | $1.94M derived: sum of 3 quarters · filed 2025-08-12 | $2.63M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $617.00K 10-Q · filed 2025-05-13 | $1.38M derived: sum of 2 quarters · filed 2025-05-13 | $2.07M derived: sum of 3 quarters · filed 2025-05-13 | $2.44M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $763.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-26 | $1.45M derived: sum of 2 quarters · filed 2025-03-26 | $1.82M derived: sum of 3 quarters · filed 2025-03-26 | $2.13M 10-K · filed 2025-03-26 |
| 2023-09-30 | $689.00K 10-Q · filed 2024-11-12 | $1.06M derived: sum of 2 quarters · filed 2024-11-12 | $1.37M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $373.00K 10-Q · filed 2024-08-13 | $679.00K 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $306.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $840.00K 10-K · filed 2024-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |